Statin use reduces the risk of dementia in elderly patients: A nationwide data survey and propensity analysis

Journal of Internal Medicine

Volumn 277, Issue 3, 2015, Pages 343-352

  Wu, C K ^a,b   Yang, Y H ^c,d   Lin, T T ^a   Tsai, C T ^a   Hwang, J J ^a   Lin, J L ^a   Chen, P C ^d   Chiang, F T ^a   Lin, L Y ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Atorvastatin; Dementia; Propensity score; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMENTIA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; HEALTH SURVEY; HUMAN; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; TAIWAN;

EID: 84927172893     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12262     Document Type: Article

References (23)

1. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Cochrane review on 'statins for the treatment of dementia'. Int J Geriatr Psychiatry 2013; 28: 119-26.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
3. Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001; 57: 1089-93.
4. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 2008; 12: 2255-62.
5. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein e genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995; 45: 1092-6.
6. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein e epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-55.
7. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61: 705-14.
8. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 2009; 80: 13-7.
9. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71: 344-50.
10. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 2010; 21: 95-102.
11. Sparks L. Statins and cognitive function. J Neurol Neurosurg Psychiatry 2009; 80: 1-2.
12. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006; 40: 1880-3.
13. Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003; 22: 77-88.
14. Chiang TL. Taiwan's 1995 health care reform. Health Policy 1997; 39: 225-39.
15. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004; 27: 1605-9.
16. Rosenbaum Paul R, Rubin Donald B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
17. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: Leade. Neurology 2010; 74: 956-64.
18. Burns MP, Noble WJ, Olm V, et al. Apolipoprotein e and fibrillar abeta in amyloid plaques. Brain Res Mol Brain Res 2003; 110: 119-25.
19. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8: 890-9.
20. Ryglewicz D, Rodo M, Kunicki PK, et al. Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002; 203-204: 195-7.
21. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23: 871-80.
22. Michikawa M, Yanagisawa K. Apolipoprotein e4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res 1998; 54: 58-67.
23. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012; 46: 549-57.